Cell-Gene-Rx-From-Promise-to-Practice—to-Access

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawThe cell and gene therapy (CGT) pipeline is expanding rapidly, with 39 products approved by the FDA as of September 2025 and as many as 85 expected by 2032. Yet access remains a major hurdle, experts noted during a panel at the NASP 2025 Annual Meeting & Expo, in Denver.“Gene therapy isn’t brand-new anymore, but in many ways we still need to move out of the pilot phase,” said Joshua Weber